Reneo Pharmaceuticals LC-FAOD REN001 Clinical Trial Update

August 18, 2022 01:02:07
Reneo Pharmaceuticals LC-FAOD REN001 Clinical Trial Update
MitoAction Expert Series
Reneo Pharmaceuticals LC-FAOD REN001 Clinical Trial Update

Aug 18 2022 | 01:02:07

/

Show Notes

There was much discussion about current research in FAODs at our recent International Metabolic conference last month. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study.

Other Episodes

Episode 0

July 07, 2020 01:06:11
Episode Cover

Exercise and Nutrition Therapy for Mitochondrial Disease - Dr. Mark Tarnopolsky - 12/2/2016

Dr. Tarnopolsky, Professor of Pediatrics and Medicine, President and CEO, Exerkine Corporation, and Director of Neuromuscular and Neurometabolic Clinic at McMaster University Medical Center,...

Listen

Episode

December 16, 2025 01:21:01
Episode Cover

Primary Mitochondrial Disease Evaluations: The evolving role of muscle biopsy

Genetic testing and muscle biopsies are important tools in diagnosing mitochondrial disease, but sometimes it can be confusing how and when they are used....

Listen

Episode 0

July 03, 2020 00:58:26
Episode Cover

BioElectron Update - Guy Miller & Matthew Klein - 6/23/2017

uy Miller, BioElectron’s CEO, and Matthew Klein, its Chief Medical Officer, will discuss the following: Challenges in the development of drugs for mitochondrial disease...

Listen